Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amelia Barrett

Neurology Lone Tree, CO Medical Doctor

NPI 1790802254 CMS profile 81793

10103 Ridgegate Pkwy, Suite 125, Lone Tree, CO 80124

Open in the dashboard

General payments

$7,962

334 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amelia Barrett of Lone Tree, CO is reported in the CMS Open Payments database as having received $7,962 across 334 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $89 2
2023 General $950 31
2022 General $2,017 72
2021 General $1,587 57
2020 General $1,007 46
2019 General $2,313 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amelia Barrett
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Amelia Barrett were reported at $89. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Amelia Barrett Neurology median Middle half National median
2019 $2,313 $474 $118–$2,177 $163
2020 $1,007 $367 $82–$2,309 $114
2021 $1,587 $438 $104–$2,547 $132
2022 $2,017 $442 $103–$2,388 $149
2023 $950 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $89 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $891 28 payments
  2. AbbVie, Inc. $788 44 payments
  3. Genzyme Corporation $658 26 payments
  4. Neurocrine Biosciences, Inc. $580 14 payments
  5. Allergan Inc. $476 25 payments
  6. Biohaven Pharmaceuticals, Inc. $447 7 payments
  7. Teva Pharmaceuticals USA, Inc. $385 28 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $375 10 payments
  9. Impel Pharmaceuticals Inc. $373 2 payments
  10. Lilly USA, LLC $360 16 payments
  11. Other $2,629 134 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,962 334 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $822 17 payments
  2. AIMOVIG $745 30 payments
  3. AUBAGIO $540 19 payments
  4. UBRELVY Neuroscience $420 24 payments
  5. INGREZZA $278 6 payments
  6. Trudhesa $276 1 payment
  7. EMGALITY $260 13 payments
  8. QULIPTA $253 15 payments
  9. UBRELVY Neuroscience $239 9 payments
  10. Ajovy $231 21 payments
  11. Other $4,301 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

26

Median for Psychiatry & Neurology: 100

Drug cost

$1,060

Median for Psychiatry & Neurology: $2,986

Branded share of claims

42.3%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Divalproex Sodium Er Divalproex Sodium Brand 11 $841
Gabapentin Generic 15 $219

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record